Milan (Italy), 12 November 2012 – The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 30 September 2012. The most important elements were:
- The analysis of the...
More
Milan (Italy), 12 November 2012 – The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 30 September 2012. The most important elements were:
- The analysis of the clinical trial progress: in particular the positive interim data of the randomised Phase II data of NGR-hTNF in combination with doxorubicin in soft tissue sarcomas;
- The increase of revenues to € 2.8 million from the development of new cell and gene therapy treatments for third parties;
- Approval of balance sheet and income statement pursuant to Art. 2446 of the Italian Civil Code.
Claudio Bordignon, Chairman of the Board and CEO of MolMed, commented: “The interim analysis of the randomised Phase II study of NGR-hTNF in soft tissue sarcomas shows a statistically significant superiority of the arm treated with the dose of 0.8 µg/sqm administered weekly in combination with doxorubicin. According to protocol design the study wi
Less
